Market Cap
US$125.3m
Last Updated
2020/09/21 05:39 UTC
Data Sources
Company Financials
Executive Summary
ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products. More Details
Risk Analysis
Snowflake Analysis
Flawless balance sheet and overvalued.
Similar Companies
Share Price & News
How has ANGLE's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ANPC.Y has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
0%
ANPC.Y
0.6%
US Medical Equipment
0.08%
US Market
1 Year Return
n/a
ANPC.Y
14.8%
US Medical Equipment
12.8%
US Market
Return vs Industry: Insufficient data to determine how ANPC.Y performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how ANPC.Y performed against the US Market.
Shareholder returns
| ANPC.Y | Industry | Market | |
|---|---|---|---|
| 7 Day | 0% | 0.6% | 0.08% |
| 30 Day | -13.0% | 1.2% | -1.8% |
| 90 Day | n/a | 11.5% | 7.2% |
| 1 Year | n/a | 15.8%14.8% | 15.3%12.8% |
| 3 Year | 23.6%23.6% | 72.3%67.9% | 39.2%29.9% |
| 5 Year | n/a | 148.2%129.3% | 88.3%67.1% |
Price Volatility Vs. Market
How volatile is ANGLE's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is ANGLE undervalued compared to its fair value and its price relative to the market?
3.19x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ANPC.Y's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ANPC.Y's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ANPC.Y is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: ANPC.Y is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ANPC.Y's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ANPC.Y is good value based on its PB Ratio (3.2x) compared to the US Medical Equipment industry average (4.1x).
Next Steps
Future Growth
How is ANGLE forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
26.1%
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ANGLE has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Examine ANGLE's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on theOTC Markets Website. If you are looking for more of a qualitative research into the company, you can access ANGLE's filings and announcementshere.
- Explore growth companies in the Healthcare industry.
Past Performance
How has ANGLE performed over the past 5 years?
-19.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ANPC.Y is currently unprofitable.
Growing Profit Margin: ANPC.Y is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ANPC.Y is unprofitable, and losses have increased over the past 5 years at a rate of 19.7% per year.
Accelerating Growth: Unable to compare ANPC.Y's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ANPC.Y is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.2%).
Return on Equity
High ROE: ANPC.Y has a negative Return on Equity (-30.91%), as it is currently unprofitable.
Next Steps
Financial Health
How is ANGLE's financial position?
Financial Position Analysis
Short Term Liabilities: ANPC.Y's short term assets (£23.6M) exceed its short term liabilities (£2.4M).
Long Term Liabilities: ANPC.Y's short term assets (£23.6M) exceed its long term liabilities (£1.6M).
Debt to Equity History and Analysis
Debt Level: ANPC.Y is debt free.
Reducing Debt: ANPC.Y had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ANPC.Y has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ANPC.Y has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 23.9% each year.
Next Steps
Dividend
What is ANGLE current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ANPC.Y's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ANPC.Y's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ANPC.Y's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ANPC.Y's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ANPC.Y's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.8yrs
Average management tenure
CEO
Andrew David Newland (58 yo)
no data
Tenure
UK£244,000
Compensation
Mr. Andrew David William Newland, Meng, ACA founded ANGLE Plc in 1994 and serves as its Group Chief Executive. Mr. Newland founded Provexis, the first ever spin-out of Rowett Institute, Europe’s leading nu ...
CEO Compensation Analysis
Compensation vs Market: Andrew David's total compensation ($USD316.10K) is below average for companies of similar size in the US market ($USD589.30K).
Compensation vs Earnings: Andrew David's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | no data | UK£244.00k | 4.09% £ 5.1m | |
| CFO, Finance Director | 16.5yrs | UK£153.00k | 0.39% £ 488.8k | |
| Head of Clinical Laboratories | 0.25yr | no data | no data | |
| VP & Chief Executive Officer of ANGLE Biosciences Inc | 2.83yrs | no data | no data | |
| Director of Manufacturing & Regulatory Affairs | 2.67yrs | no data | no data | |
| Business Development Director | 6.83yrs | no data | no data |
2.8yrs
Average Tenure
55yo
Average Age
Experienced Management: ANPC.Y's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | no data | UK£244.00k | 4.09% £ 5.1m | |
| CFO, Finance Director | 16.5yrs | UK£153.00k | 0.39% £ 488.8k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Chairman | 13yrs | UK£17.00k | 0.012% £ 14.5k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Non-Executive & Senior Independent Director | 1.67yrs | UK£17.00k | 0.0058% £ 7.3k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 2.67yrs | no data | no data | |
| Member of Scientific Advisory Board | 5.25yrs | no data | no data | |
| Member of Scientific Advisory Board | 5.17yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
5.3yrs
Average Tenure
58yo
Average Age
Experienced Board: ANPC.Y's board of directors are considered experienced (5.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
ANGLE plc's company bio, employee growth, exchange listings and data sources
Key Information
- Name: ANGLE plc
- Ticker: ANPC.Y
- Exchange: OTCPK
- Founded: 1994
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: UK£96.703m
- Listing Market Cap: UK£125.279m
- Shares outstanding: 172.68m
- Website: https://www.angleplc.com
Number of Employees
Location
- ANGLE plc
- Surrey Research Park
- 10 Nugent Road
- Guildford
- Surrey
- GU2 7AF
- United Kingdom
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| AGL | AIM (London Stock Exchange AIM Market) | Yes | Ordinary Shares | GB | GBP | Mar 2004 |
| ANPC.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Mar 2004 |
| DWV | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Mar 2004 |
| ANPC.Y | OTCPK (Pink Sheets LLC) | SPONSONRED ADR | US | USD | Oct 2014 |
Biography
ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products. It develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor ce ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/09/21 05:39 |
| End of Day Share Price | 2020/08/28 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.